Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00207090 · ClinicalTrials.gov registry record · Phase 1

Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced Cancer

A Phase 1 study of Neoplasms and Advanced Solid Tumors, sponsored by R-Pharm.

Completed
Registry status
Phase 1
Development phase
19
Enrollment target
1
Study location

NCT00207090 is a Phase 1 study of Neoplasms and Advanced Solid Tumors that has completed, run by R-Pharm. The registered enrollment target is 19 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00207090, a Phase 1 study of Neoplasms and Advanced Solid Tumors, has completed, sponsored by R-Pharm.

COMPLETED
Registry status
Phase 1
Development phase
19 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to test how rifampin affects the removal of BMS-247550 (ixabepilone) from the body.

Conditions Studied

Neoplasms Advanced Solid Tumors

Interventions

  • DRUG Rifampin
  • DRUG ixabepilone

Study Locations (1)

Ohio

  • The Cleveland Clinic Foundation - Cleveland

Trial Details

FieldValue
Enrollment Target 19 participants
Start Date 2005-09
Est. Completion 2008-11
Phase Phase 1

Sponsor

R-Pharm

19 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00207090

The ClinicalTrials.gov registry entry for NCT00207090 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (99% lower). The listed sponsor is R-Pharm, which has 19 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which Rifampin is the first listed.

NCT00207090 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT00207090 about?

NCT00207090 is a clinical study titled "Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced Cancer". The purpose of this study is to test how rifampin affects the removal of BMS-247550 (ixabepilone) from the body.

What is the current status of trial NCT00207090?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2005-09. Estimated completion is 2008-11.

What conditions does trial NCT00207090 study?

This clinical trial studies the following conditions: Neoplasms, Advanced Solid Tumors.

What interventions are being tested in trial NCT00207090?

The interventions under investigation include: Rifampin (DRUG), ixabepilone (DRUG).

Who is sponsoring clinical trial NCT00207090?

This trial is sponsored by R-Pharm, which has 19 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00207090 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Neoplasms

All registered trials for this condition

Advanced Solid Tumors

All registered trials for this condition

Ohio

All trials with a study site in Ohio

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.